Probing amylin fibrillation at an early stage via a tetracysteine-recognising fluorophore by Wang, Shih Ting et al.
This is a repository copy of Probing amylin fibrillation at an early stage via a 
tetracysteine-recognising fluorophore.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/135439/
Version: Published Version
Article:
Wang, Shih Ting, Lin, Yiyang, Hsu, Chia Chen et al. (3 more authors) (2017) Probing 
amylin fibrillation at an early stage via a tetracysteine-recognising fluorophore. Talanta. pp.
44-50. ISSN 0039-9140 
https://doi.org/10.1016/j.talanta.2017.05.015
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Contents lists available at ScienceDirect
Talanta
journal homepage: www.elsevier.com/locate/talanta
Probing amylin ﬁbrillation at an early stage via a tetracysteine-recognising
ﬂuorophore
Shih-Ting Wang, Yiyang Lin, Chia-Chen Hsu, Nadav Amdursky, Christopher D. Spicer, Molly
M. Stevens⁎
Department of Materials, Department of Bioengineering and Institute for Biomedical Engineering, Imperial College London, Exhibition Road, London SW7
2AZ, United Kingdom
A R T I C L E I N F O
Keywords:
Amylin
FlAsH
Fibrillation
Early detection
Amyloid inhibitor
Glycosaminoglycan
A B S T R A C T
Amyloid ﬁbrillation is a nucleation-dependent process known be involved in the development of more than 20
progressive and chronic diseases. The detection of amyloid formation at the nucleation stage can greatly
advance early diagnoses and treatment of diseases. In this work, we developed a new assay for the early
detection of amylin ﬁbrillation using the biarsenical dye 4,5-bis(1,3,2-dithiarsolan-2-yl)ﬂuorescein (FlAsH),
which could recognise tetracysteine motifs and transform from non-ﬂuorescent form into strongly ﬂuorescent
complexes. Due to the close proximity of two cysteine residues within the hydrophilic domain of amylin, a non-
contiguous tetracysteine motif can form upon amylin dimerisation or oligomerisation, which can be recognised
by FlAsH and emit strong ﬂuorescence. This enables us to report the nucleation-growth process of amylin
without modiﬁcation of the protein sequence. We showed that the use of this assay not only allowed the tracking
of initial nucleation events, but also enabled imaging of amyloid ﬁbrils and investigation of the eﬀects of amyloid
inhibitor/modulator toward amylin ﬁbrillation.
1. Introduction
Type II diabetes (T2D) is an epidemic disease that leads to β-cell
failure and many chronic macro- and microvascular complications [1].
One of the causes has been found to involve the ﬁbrillation of amylin
(or islet amyloid polypeptide, IAPP), which is co-secreted with insulin
[2]. Amylin is a 37-amino acid peptide hormone, which possesses a
disulphide bond between the cysteine residues Cys 2 and Cys 7 at the
N-terminal domain (amylin residues 1–19), and carries three positive
charges throughout the structure that stabilise the protein structure
and give bioactivity. The over-production of amylin associated with
insulin resistance and hyperinsulinemia in T2D triggers a nucleation-
dependent self-assembly of amylin into intracellular or extracellular
amyloid deposits, which is modulated by the core amyloidogenic
sequence at the C-terminal domain (amylin residues 20–29). The
self-assembly of amyloid proteins into ﬁbrils is reported to undergo a
nucleated polymerisation process via a two-step kinetic process. Fibril
growth is triggered upon formation of a “critical nucleus” of amyloid
aggregates in the early nucleation process, in which a large mass
percentage of the small protein aggregates are converted into ﬁbrils at
an exponential rate. These amyloid aggregates (i.e. oligomers) formed
at the early stage have been considered as the major cytotoxic species
[3–5]. It is therefore important to be able to detect these early
aggregation species in order to prevent subsequent amyloid-induced
pathology.
Amyloid oligomers have been reported in diﬀerent sizes and shapes,
including dimers, tetramers, hexamers and dodecamers [6–15]. However,
few methods are able to detect and quantify the extent of oligomer
formation and whether such species will subsequently lead to the
formation of amyloid ﬁbrils. Fluorescence has been the most commonly
used technique to study the ﬁbrillation of amyloid proteins. Several
amyloid-reporting dyes such as Thioﬂavin-T (ThT), Congo red, Nile Red
and 8-anilino-1-naphthalenesulphonic acid could indicate the formation
of β-sheets or hydrophobic domains during amyloid ﬁbrillation [8,16–19].
However, such ﬂuorescent dyes targeting the core β-sheet region, only
show increased ﬂuorescence when a critical amount of ﬁbril nucleus is
formed, making them relatively insensitive to the formation of oligomers.
In particular, ThT is widely exploited in detecting large ﬁbrillar aggregates
both in vitro and in vivo since it selectively binds to amyloid ﬁbrils and
emits bright ﬂuorescence upon binding. However, the ThT assay is not
suitable for monitoring the early aggregation events, as it does not bind to
amyloid oligomers. New methods using two individual components of
ﬂuorescent protein fragments via bimolecular ﬂuorescence complementa-
tion [20], FRET [21] and aggregation-induced emission [22], have been
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developed for early detection of amyloid ﬁbrillation. Recently, a MRI
(magnetic resonance imaging) probe that pairs a magnetic nanostructure
with an antibody has also been reported to detect the amyloid β oligomers
in the brain that are responsible for the onset of disease [23].
In the work presented here, we have developed a new strategy to
detect the early stages of amylin ﬁbrillation in its native sequence, by
using the protein sequence-selective biarsenical dye, 4,5-bis(1,3,2-
dithiarsolan-2-yl)ﬂuorescein (FlAsH), which exhibits increased ﬂuor-
escence upon reacting with oriented tetracysteine motifs. The ﬂuoro-
genic nature of the dye is based on an eﬃcient thiol-arsenic ligand
exchange reaction that converts the non-ﬂuorescent 1,2-ethanedithiol
(EDT)-bound form of FlAsH into strongly ﬂuorescent complexes [24].
FlAsH has been shown to eﬃciently recognise the amino acid sequence,
CCXXCC (where X represents any amino acids other than cysteine)
allowing its use for imaging cells and studying protein-protein inter-
actions [25,26]. FlAsH can also recognise two proximal bicysteine
motifs (Cys-Cys) on separate strands when held in the correct orienta-
tion, allowing it to be used as a reporter for protein folding [24,25].
Recent work by Lee et al. has demonstrated the use of FlAsH to record
the aggregation process of amyloid-β (Aβ), by modifying the natural
protein sequence with two consecutive cysteines, which subsequently
become proximal (~7 Å) in the assembled state [27]. However,
importantly this approach requires covalent conjugation of two
cysteines which alters the native form of the amyloid protein. In this
work, we demonstrate that FlAsH can be used to monitor the
ﬁbrillation of amylin, without needing to attach additional amino
acids. Since amylin possesses two cysteines (Cys2 and Cys7) at the
N-terminal domain, the aggregation of two or more amylin molecules
will generate tetracysteine moieties that can be recognised by FlAsH.
Particularly, the inter-strand proximity of amylin was reported to be
~4.7 Å corresponding to the hydrogen bond spacing of two β-strand
layers in the ﬁbrillar state [28]. This allows the proximal orientation of
four cysteines and eﬀective binding of FlAsH to amylin. In principle,
this method could be utilised to monitor the formation of amylin
oligomers or even dimers. By taking advantage of the enhanced FlAsH
ﬂuorescence, this assay was also applied to image amylin ﬁbrils with
ﬂuorescence microscopy. Furthermore, FlAsH was used as a probe to
investigate the extent of amylin ﬁbrillation in the presence of small-
molecule inhibitor and glycosaminoglycan (GAG)-based modulators.
Beyond the early detection study of amyloid ﬁbrillation, we anticipate
this assay can be applied in the ﬁeld of high-throughput screening of
amyloid inhibitors.
2. Materials and methods
2.1. Materials
Human amylin was purchased from Bachem. FlAsH and all the
other chemicals were purchased from Sigma-Aldrich (U.K.). Milli-Q
water (18 MΩ) was used for the experiments.
2.2. Pre-treatment of amylin
To remove pre-existing aggregation structures, amylin powder was
dissolved in hexaﬂuoro-2-propanol (HFIP) in a sealed vial for 8 h at
room temperature. After evaporating the solvent with N2 gas, the pre-
treated amylin powder was stored at −20 °C.
2.3. Transmission electron microscopy (TEM) imaging
Amylin ﬁbrils for TEM imaging were prepared by ageing amylin in
20 mM phosphate buﬀer (pH 7.5) for at least 2 days at room
temperature. The sample was deposited on carbon ﬁlm supported
TEM grids and stained with 1 wt% uranyl acetate prior to imaging.
TEM imaging was performed on a JEOL 2100F microscope with an
acceleration voltage of 200 kV.
2.4. Atomic force microscopy (AFM) imaging
Amylin ﬁbrils for AFM imaging were prepared by ageing amylin in
20 mM phosphate buﬀer (pH 7.5) for at least 2 days at room
temperature. The sample was drop-cast on an oxygen plasma treated
silicon wafer and left to dry in air prior to imaging. AFM imaging was
performed on an AFM 5500 Microscope (Keysight Technologies,
previously Agilent) in tapping mode in air. A HQ: NSC15/Al BS tip
(μmasch) was used for the topography imaging (tip radius of 8 nm,
resonance frequency of 325 kHz, force constant of 40 N m−1).
2.5. Circular dichroism (CD)
The secondary structures of amylin monomer and ﬁbrils were
recorded by Jasco-715 circular dichroism spectrometer. The pre-
formed ﬁbrils were prepared by incubating amylin powder with
20 mM phosphate buﬀer (pH 7.5) for 24 h at room temperature. The
samples were loaded in a quartz cell with an optical path length of
1.0 mm. The scanning speed was 50 nm/min, the data pitch was
0.1 nm, the response time was 4 s, and the band width was 2 nm.
The average spectrum from two measurements was reported.
2.6. Confocal imaging
Amylin samples for confocal microscopy were prepared by ageing
25 μM of amylin in 20 mM, pH 7.5 phosphate buﬀer at room
temperature for 2 days, followed by TCEP (1 mM) treatment for
30 min. FlAsH (100 μM) was added to the pre-treated amylin solution
and incubated for 24 h at room temperature. Then the solution was
drop-casted, mounted with FluorSave™ Reagent (Calbiochem), and left
to dry on the glass slide prior to imaging. Confocal imaging was carried
out with a Leica SP5 inverted confocal microscope using a 100×1.4 NA
oil immersion objective. The laser wavelength excitation and emission
ﬁlters for FlAsH were 488 nm and 503–555 nm respectively. For post-
processing of the images, 16-bit raw confocal image stacks were
deconvolved using Huygens Deconvolution software (Scientiﬁc
Volume Image), and a confocal z-stack montage was created from the
3D data sets using ImageJ.
2.7. Native polyacrylamide gel electrophoresis (PAGE)
Native gel electrophoresis were performed using amylin samples
that contained 0.43 mM of amylin, 1 mM TCEP and diﬀerent concen-
trations of FlAsH (0.22 mM, 0.43 mM, and 0.86 mM) in phosphate
buﬀer (20 mM, pH 7.5). Amylin ﬁbrils were prepared by ageing the
amylin solution (0.5 mM) for at least 24 h in the phosphate buﬀer
(20 mM, pH 7.5). To run a native PAGE, the samples were mixed with
native sample buﬀer (Bio-Rad), and electrophoresed in 4–20% Mini-
PROTEAN® TGX™ Precast Protein Gels (Bio-Rad) in Tris-Glycine
running buﬀer (Bio-Rad) at 80 V for 1.5 h at room temperature. The
result was visualised with a BioSpectrum Imaging System (UVP) with
VisionWorks LS Software (UVP) and the molecular weights were
approximated using Precision Plus Protein™ Kaleidoscope™
Standards (Bio-Rad).
2.8. ThT assay
ThT assay was performed in a 384-well plate with a total volume of
80 μL. The amylin solution was prepared at a concentration of
31.25 μM in phosphate buﬀer (20 mM, pH 7.5), and diluted to ﬁnal
concentrations of 25, 20, 10, and 5 μM with buﬀer. Then, 8 μL of ThT
stock solution (100 μM) was added to the peptide solution.
Fluorescence kinetics were measured on Perkin Elmer EnSpire plate
reader, with a time interval of 2 min. The excitation wavelength of ThT
ﬂuorescence was 440 nm, and the emission wavelength was 485 nm.
The lag time (tlag) and the time at half ﬂuorescence maximum (t1/2)
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were calculated according to the method reported by Arosio and
colleagues [29]. For the measurement of ﬁbrillation kinetics in the
presence of glycosaminoglycans (GAGs), 8 μL of GAG solution (0.5 mg/
mL in deionised water) were added to the amylin (10 μM) solution, and
ThT (10 μM) was immediately added to the amylin/GAG solution prior
to ﬂuorescence measurement.
2.9. FlAsH binding assay
FlAsH assay was performed in a 384-well plate with a total volume
of 80 μL. The amylin solution was prepared at a concentration of
25 μM in phosphate buﬀer (20 mM, pH 7.5). To reduce the disulphide
bond, TCEP (1 mM) was added to the solution and left undisturbed for
15 min at room temperature. Final concentrations of 15, 12, 9, 6, and
3 μM of TCEP-treated amylin were prepared in buﬀer, followed by the
addition of 8 μL of FlAsH solution (30 μM) to the peptide solution.
Fluorescence kinetics were measured on Perkin Elmer EnSpire plate
reader, with a time interval of 2 min. The excitation wavelength of
FlAsH ﬂuorescence was 480 nm, and the emission wavelength was
535 nm.
2.10. Study of amyloid modulator/inhibitor with FlAsH assay
To screen the eﬀect of GAGs on amylin ﬁbrillation, 8 μL of GAG
solutions (0.5 mg/mL in deionized water) were added to the TCEP-
treated amylin (10 μM) solution, followed by the addition of FlAsH
(3 μM). The solution was left undisturbed in the dark for 2.5 h prior to
ﬂuorescence spectra measurement (Ex=480 nm, Em=490–650 nm).
The inhibiting eﬀects of epigallocatechin-3-gallate (EGCG) were de-
monstrated by adding the inhibitor solutions at diﬀerent concentra-
tions to the TCEP-treated amylin (10 μM) solution, followed by the
addition of FlAsH (3 μM). The solution was left undisturbed in the dark
for 1.5 h prior to ﬂuorescence spectra measurements. The results were
plotted by recording the maximum (528 nm) of each spectrum.
3. Results and discussion
3.1. Binding of FlAsH to amylin
As shown in Scheme 1, the aggregation of amylin results in the
formation of a non-contiguous tetracysteine motif that can be recog-
nised by FlAsH after cleaving the disulphide bond with tris(2-carbox-
yethyl)phosphine (TCEP) to produce reduced cysteines. In this process,
complexation of the tetracysteine moieties and FlAsH resulted in
increased ﬂuorescence. The ﬁbrillation of amylin is known to be
accompanied by the formation of β-sheets, driven by multiple hydrogen
bonding and hydrophobic interactions between amyloid sequences
(residues 20–29). CD spectra conﬁrmed a conformational change of
amylin from random coils into extensive β-sheets in aqueous solution
(Fig. S1), where the non-aggregated amylin showed a signal at 202 nm,
and the mature ﬁbril showed a peak at 218 nm due to the existence of
β-sheets.
Amylin ﬁbrillation was known to be governed by the core amyloi-
dogenic sequence at the C-terminal domain (amylin residues 20–29)
[30,31]. Since the binding site of FlAsH to amylin was located at the N-
terminal domain, which is not responsible for protein self-assembly
[32,33], the addition of FlAsH was not supposed to induce aggregation
of amylin. Actually, the ﬁbrillation kinetics were not noticeably altered
after cysteine reduction (Fig. S2). This also agrees with the previous
study by Lee et al. [27], in which FlAsH did not alter the amyloid
ﬁbrillation pathway of cysteine-modiﬁed Aβ. The eﬀective binding of
FlAsH to reduced-cysteine amylin was further demonstrated by
ﬂuorescence spectroscopy with a ﬁve-fold increase in ﬂuorescence
intensity being observed for amylin in its ﬁbrillar state compared to
the monomeric form (Fig. 1). In addition, FlAsH exhibited low
ﬂuorescence in both monomeric and ﬁbrillar amylin samples in the
absence of TCEP, indicating that the cleavage of disulphides was crucial
for the detection of intermolecular protein assembly.
3.2. Imaging of amylin ﬁbrils with FlAsH
Amylin ﬁbrillation was further conﬁrmed by transmission electron
microscopy (TEM) and atomic force microscopy (AFM), showing
mature amylin ﬁbrils had an average height of 5 nm, width of 10 nm
and length of several hundred nanometres (Fig. 2a, S3). Here, the ﬁve-
fold ﬂuorescence enhancement of FlAsH upon reacting with aggregated
amylin (Fig. 1) has enabled us to image the amylin ﬁbrils with good
Scheme 1. Schematic view of the detection of amylin nucleation by FlAsH. The mechanism of amyloid ﬁbrillation involves multiple processes, in which protein oligomers transform
ﬁrst into protoﬁbrils and then further grow into amyloid ﬁbrils. FlAsH can react with dimerised amylin through four reduced thiol groups in close proximity, formed by cleaving the
intrinsic disulphide bonds at the N-terminal region by TCEP. The inset ﬁgure shows the “turn-on” ﬂuorescence by the tetracysteine recognitionby cleaving the intrinsic disulphide bonds
at the N-terminal region by TCEP.
Fig. 1. Fluorescence spectra of FlAsH (1 μM) in the presence of amylin (10 μM)
monomers and ﬁbrils, and with or without cysteine reduction by TCEP (1 mM).
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signal-to-noise ratio by confocal microscopy, which could be consid-
ered as a complementary technique for imaging of amyloid ﬁbrils. As
shown in Fig. 2b, S4 and Video S1, FlAsH-labelled amylin ﬁbrils
further aggregated into a 3D network, which displayed an average
thickness of 5.20 ± 1.18 µm along the axis of the imaging sections. The
co-localisation of individual amylin ﬁbrils and FlAsH ﬂuorescence
conﬁrmed the ﬂuorescence enhancement was due to FlAsH-amylin
complexation. As shown in Fig. S5, a bonus for FlAsH labelling was
that the arsenic ligand did not interact with reduced glutathione (GSH,
10 mM), which is commonly presented in living cells at a millimolar
concentration [34,35].
Supplementary material related to this article can be found online
at http://dx.doi.org/10.1016/j.talanta.2017.05.015.
3.3. Early detection of amylin ﬁbrillation with FlAsH
ThT kinetic assay is the typical method that has been established to
study the self-assembly of amyloid proteins. However, the ThT assay is
Fig. 2. Imaging of amylin ﬁbrils by (a) TEM and (b) confocal microscopy. In (b), the ﬁbrillar structures with green ﬂuorescence supports the binding of FlAsH to amylin.
Fig. 3. Comparison of FlAsH and ThT assays in the detection of amylin ﬁbrillation. (a) ThT and (b) FlAsH assay monitoring the amylin ﬁbrillation kinetics. (c) Kinetic assay of amylin
(10 μM) ﬁbrillation with FlAsH (1 μM) and ThT (1 μM), showing the early-detection of amylin nucleation with FlAsH. (d) Fluorescence spectra of FlAsH in amylin solutions (20 μM)
with and without excess TCEP (50 mM).
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not able to detect oligomer formation at the early stage of protein
ﬁbrillation. As shown in Fig. 3a, the kinetics of amylin self-assembly
displayed a sigmoidal shape, in which the nucleation phase (or lag
phase) showed low ﬂuorescence and was followed by a transition zone
(the growth phase) that exhibited an exponential increase in the
emission intensity. At the ﬁnal stage, the maximised and stabilised
ﬂuorescence emission represented a steady state where the ﬁbril
concentration reached its equilibrium value. The ﬁbrillation kinetics
were dependent on the protein concentration, which could be deter-
mined by ﬁtting the sigmoidal curves to extrapolate the lag time (tlag,
the duration of lag phase), and the half time (t1/2, the amplitude of
nucleation-growth transition) (Fig. S6). As shown in Fig. S6a, tlag at low
emission intensity was calculated to be within 1–3.5 h depending on
the amylin concentration between 5–25 μM.
Unlike the ThT assay, amylin ﬁbrillation reported by FlAsH ﬂuores-
cence showed a rapid increase in emission intensity, with the ﬂuorescence
enhancement being correlated with protein concentration (Fig. 3b). As
shown in Fig S7, a linear correlation between the increasing rate of
ﬂuorescence intensity and protein concentration was found. This suggests
that molecular association between two amylin proteins could rapidly form
oligomeric intermediates, which served as nucleation seeds for ﬁbril
growth and elongation [36–38]. Native polyacrylamide gel electrophoresis
(PAGE) showed the formation of amylin oligomers (~10 kDa) that could
be detected by FlAsH (Fig. S8). Amylin aggregation into large ﬁbrils could
be conﬁrmed by the 1.2 times enhanced ﬂuorescence intensities of the
freshly prepared amylin solution, compared to the ﬁbril samples.
The advantages of FlAsH over ThT in monitoring the initial events
of amylin ﬁbrillation were further demonstrated when the ﬂuorescence
emission of 1 μM of FlAsH (Ex=480 nm and Em=535 nm) and ThT
(Ex=440 nm and Em=485 nm) were simultaneously recorded in the
presence of 10 μM amylin. It is noted that the FlAsH ﬂuorescence
reaching its maximum at 1.5 h preceded the ThT-monitored growth
phase associated with amyloid ﬁbril formation (Fig. 3c). This phenom-
enon is likely to originate from the diﬀerent ﬂuorescence emission
mechanisms of FlAsH and ThT, where ThT speciﬁcally targets β-sheet
structures, while FlAsH can recognise the formation of dimers and
oligomers at the early stage. Moreover, addition of excess TCEP
(50 mM) to the amylin/FlAsH conjugates showed a reduction in the
ﬂuorescence intensity (Fig. 3d), indicating that enhanced ﬂuorescence
originated from covalent bonding between FlAsH and amylin.
3.4. Examination of amyloid inhibitor and modulator with FlAsH
We applied the FlAsH assay to examine amylin ﬁbrillation in the
presence of amyloid inhibitors and modulators. It is known that
polyphenol derivatives such as epigallocatechin-3-gallate (EGCG) can
redirect the amyloid aggregation pathway and inhibit the ﬁbril forma-
tion [39–41]. Indeed, the inhibition eﬀect of EGCG (50 μM) towards
amylin aggregation was observed from the decrease of FlAsH ﬂuores-
cence in a concentration-dependent manner (Fig. 4). By ﬁtting the
concentration-ﬂuorescence curve, the IC50 of EGCG was determined to
be 0.3 μM (Fig. 4b).
The FlAsH assay was also applied to screen the eﬀect of GAG-based
amyloid modulators. GAGs are a subfamily of carbohydrate polymers
that function in various biological processes, with changes in the
chemical structure (e.g. charge, acetylation, and sulphonation) signiﬁ-
cantly aﬀecting biological activity. Among the macromolecules, those
containing strong negative charge lead to a strong aﬃnity for amyloid
precursors and promote nucleation into ﬁbrils [42]. In particular,
sulphated GAGs, which are abundant components of the extracellular
matrix of many tissues, have been reported to stabilise the mature
ﬁbrils and prevent dissociation and proteolytic degradation [43–45].
To distinguish the diﬀerences between GAGs in regulating amylin self-
assembly, we compared the enhanced FlAsH ﬂuorescence in amylin
solutions in the presence of ﬁve selected GAGs, dextran sulphate (G1),
heparin sulphate (G2), N-acetyl-de-O-sulphated heparin sodium salt
(G3), hyaluronic acid sodium salt (G4), and chitosan (G5). We found
that G1 and G2 showed the highest eﬀect in promoting amylin
aggregation as the strongest ﬂuorescence was noted in both cases.
Control experiments showed the ﬂuorescence increase was not due to
GAG/FlAsH interactions since GAGs themselves did not cause en-
hanced emission (Fig. 5a).
In contrast, G3, G4 and G5 did not noticeably aﬀect the self-
assembly of amylin at the same concentration. To interpret this result,
it is necessary to consider the molecular structure of the GAGs. As
shown in Fig. 5b, the GAGs consist of disaccharide repeating units with
diﬀerent anionic groups (i.e., carboxyl, and sulphate groups, except for
chitosan) on the backbones [46]. Considering the possession of four
positive charges on amylin, it is reasonable that electrostatic attractions
may dominate the GAG/amylin interactions. In the literature, charge
interactions between nanoparticles and amyloid proteins have been
shown to accelerate the ﬁbrillation process due to the generation of
localised nucleation sites, causing the enhanced propagation into ﬁbrils
[47,48]. Here, G1 and G2 possess four negative charges on each
disaccharide unit and could complex with the positively-charged
amylin more eﬀectively than G3, G4, and G5 (which have two, one,
and no charges, respectively), and result in a higher ﬁbrillation rate.
This ﬁnding was consistent with the ThT assay (Fig. S9), where a
signiﬁcant increase in ﬂuorescence was also observed in the presence of
G1 and G2 after 2.5 h, while the other GAG modulators showed less
Fig. 4. Inhibition of amylin self-association by EGCG studied by FlAsH assay. (a) Fluorescence spectra of FlAsH probe in a solution of amylin (10 μM) in the presence and absence of
EGCG. The amylin/EGCG mixtures were incubated for 1.5 h before the ﬂuorescence measured. (b) Fluorescence intensity of FlAsH probe (Ex=480 nm, Em=528 nm) in a solution of
amylin (10 μM) containing diﬀerent concentrations of EGCG. The inset ﬁgure shows the molecular structure of EGCG.
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eﬀect on amylin ﬁbrillation (Fig. S9b). It is noted that the background
of FlAsH ﬂuorescence in the GAG solutions was negligible since there
were not tetracysteine motifs or free thiols present in the backbone of
GAGs. In contrast, ThT ﬂuorescence in GAG solutions showed varied
ﬂuorescence background possibly due to the fact that rigid polysac-
charide backbones can restrict the rotational motion of ThT and
enhance its ﬂuorescence quantum yield. We anticipate that the
FlAsH assay developed here will be applicable to the discrimination
of natural amyloid modulators, and high-throughput screening of small
molecule inhibitors for amylin ﬁbrillation.
4. Conclusions
In conclusion, we have developed a new strategy to detect amylin
ﬁbrillation at an early stage using a tetracysteine-binding FlAsH dye.
This method speciﬁcally recognised the intrinsic disulphide bonds on
two adjacent amylin motifs. Importantly, the assay detected the native
structure without causing perturbation of the aggregation pathway. The
in situ eﬃcient conjugation of FlAsH to associated amylin in the
ﬁbrillar form enabled the ﬂuorescence imaging of the amyloid ﬁbrils.
Since FlAsH is known to have cell permeability [24,49], it is expected
that this method can allow localised cellular imaging of the aggregated
proteins. Compared to the commonly used ThT ﬂuorescence assay, this
method notably allowed concentration-dependent kinetics studies of
the early nucleation events, which are key features in the aggregation
mechanism of many proteins. The FlAsH assay was also able to
monitor the extent of ﬁbrillation in the presence of amylin inhibitors
and modulators. This approach applying a concentration-dependent
study, speciﬁcally recognising amino acid residues of the native protein
structure, is expected to be useful for further investigations into the
Fig. 5. Eﬀect of GAGs on the degree of amylin self-association via FlAsH assay. (a) Fluorescence intensity of FlAsH probe in a solution of amylin in the presence of GAGs (Ex=480 nm,
Em=528 nm). The amylin/GAG mixtures were incubated for 2.5 h before the ﬂuorescence intensity was measured, and the intensities were calculated relative to a control sample in the
absence of GAG. (b) Molecular structure of the GAGs (G1: dextran sulphate, G2: heparin sulphate, G3: N-acetyl-de-O-sulphated heparin sodium salt, G4: hyaluronic acid sodium salt,
G5: chitosan).
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mechanistic details controlling self-assembly in other aggregation-
prone proteins.
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